Fig. 2: Survival curves for belotecan and topotecan. | British Journal of Cancer

Fig. 2: Survival curves for belotecan and topotecan.

From: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

Fig. 2

Kaplan–Meier curves showing a PFS and b OS for belotecan and topotecan groups. p values were obtained from log-rank tests for comparisons of PFS and OS between groups. Vertical dashed line indicates 1-year OS rate. ORR objective response rate, DCR disease control rate, PFS progression-free disease, OS overall survival.

Back to article page